Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a ...

Higher hospitalization rates were associated with several chronic conditions, possibly due to a higher likelihood of ...

Hospitalization rates from respiratory syncytial virus (RSV) infection rose with age. Also, hospitalizations were more likely among nursing home residents and older adults with other health issues, ...

A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

A new study published in the Journal of American Medical Association showed that nirsevimab offers protection against a ...

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

On 12 March 2025, the World Health Organization (WHO) prequalified the first maternal respiratory syncytial virus (RSV) vaccine to protect infants ...

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...

Higher hospitalization rates were associated with several chronic conditions, possibly due to a higher likelihood of infection and increased severity of RSV disease. Blood cancer was the chronic ...